Clinical trial
PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)
NCT00182143 · McMaster University, Other · Completed
Key facts
| NCT number | NCT00182143 |
|---|---|
| Title | PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) |
| Official title | PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) |
| Lead sponsor | McMaster University, Other |
| Collaborators | Canadian Institutes of Health Research (CIHR) Canadian Critical Care Trials Group Australian and New Zealand Intensive Care Society Clinical Trials Group |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Critical Illness, Deep Venous Thrombosis |
| Intervention type | Drug |
| Interventions | LMWH (Fragmin, dalteparin), Unfractionated Heparin |
| Enrollment | 3,659 |
| Start date | May 1, 2006 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 1, 2010 |
| First posted | Sep 16, 2005 |
| Last update posted | Jan 10, 2011 |
| Countries | Australia, Brazil, Canada, Saudi Arabia, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: